Observational studyLung2026
Long-Term Prognosis of Adult Patients with Persistent Cough Post COVID-19 and Its Risk Factors: A Nationwide Prospective Study.
Observational study in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06951321 (Clinical and Pathophysiological Characteristics of Postinfectious Cough Post COVID-19 Infection), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Pathophysiological Characteristics of Postinfectious Cough Post COVID-19 Infection: a Multi-center Nationwide Research
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are few data regarding the duration, long-term prognosis of persistent cough post coronavirus disease 2019 (COVID-19). The break of COVID-19 Omicron mutant infection provides an opportunity to investigate the long-term outcome of postinfectious cough and its risk factors.
methodsIn this multicenter prospective study, we recruited patients aged ≥ 18 years with cough duration ≥ 3 weeks after COVID-19 infection during early stage of 2023 in respiratory clinics, cough assessments and laboratory investigations were conducted. Patients underwent two follow-up visits at 12 weeks and 52 weeks.
resultsA total of 1650 patients were enrolled, with an average age of 42.2 ± 14.4 years and 63.3% females. According to follow-up visits, the cough duration was 12 (8,20) weeks, and chronic cough occurred in 68.4%. Cough relieved in 90.8% within 32 weeks. At baseline, sputum eosinophilia (≥ 2.5%) was found in 21.8% (46/211) patients, fractional exhaled nitric oxide level (≥ 25 ppb) elevated in 33.9% (176/519). In addition, 17.2% (73/425) of patients showed bronchial hyperresponsiveness. Cough hypersensitivity was found in 72.5% (37/55) for capsaicin and 63.2% (48/76) for adenosine triphosphate. Multivariate cox regression analysis showed that being older (P = 0.007), higher cough VAS (P < 0.001; P = 0.001), higher CET score (P < 0.001; P = 0.03), and comorbidities (P = 0.043) were associated with chronic cough.
conclusionIn adult patients with COVID-19 Omicron infection, cough lasted for more than 8 weeks in over two thirds, and relieved within 32 weeks in majority of patients. Being older, worse cough severity, and comorbidities are the risk factors of developing chronic cough. CLINICAL TRIALS REGISTRY: ClinicalTrials.gov; No.: NCT06951321.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.